382 related articles for article (PubMed ID: 33595381)
1. Folate Receptor-Mediated siRNA Delivery: Recent Developments and Future Directions for RNAi Therapeutics.
Gangopadhyay S; Nikam RR; Gore KR
Nucleic Acid Ther; 2021 Aug; 31(4):245-270. PubMed ID: 33595381
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
Varshosaz J; Farzan M
World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
[TBL] [Abstract][Full Text] [Related]
3. Systemic Delivery of Folate-PEG siRNA Lipopolyplexes with Enhanced Intracellular Stability for In Vivo Gene Silencing in Leukemia.
Lee DJ; Kessel E; Lehto T; Liu X; Yoshinaga N; Padari K; Chen YC; Kempter S; Uchida S; Rädler JO; Pooga M; Sheu MT; Kataoka K; Wagner E
Bioconjug Chem; 2017 Sep; 28(9):2393-2409. PubMed ID: 28772071
[TBL] [Abstract][Full Text] [Related]
4. To Conjugate or to Package? A Look at Targeted siRNA Delivery Through Folate Receptors.
Salim L; Desaulniers JP
Nucleic Acid Ther; 2021 Feb; 31(1):21-38. PubMed ID: 33121373
[TBL] [Abstract][Full Text] [Related]
5. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy.
Li TS; Yawata T; Honke K
Eur J Pharm Sci; 2014 Feb; 52():48-61. PubMed ID: 24178005
[TBL] [Abstract][Full Text] [Related]
6. Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts.
Yoshizawa T; Hattori Y; Hakoshima M; Koga K; Maitani Y
Eur J Pharm Biopharm; 2008 Nov; 70(3):718-25. PubMed ID: 18647651
[TBL] [Abstract][Full Text] [Related]
7. Folic acid-decorated polyamidoamine dendrimer exhibits high tumor uptake and sustained highly localized retention in solid tumors: Its utility for local siRNA delivery.
Xu L; Yeudall WA; Yang H
Acta Biomater; 2017 Jul; 57():251-261. PubMed ID: 28438704
[TBL] [Abstract][Full Text] [Related]
8. Low molecular weight chitosan conjugated with folate for siRNA delivery in vitro: optimization studies.
Fernandes JC; Qiu X; Winnik FM; Benderdour M; Zhang X; Dai K; Shi Q
Int J Nanomedicine; 2012; 7():5833-45. PubMed ID: 23209368
[TBL] [Abstract][Full Text] [Related]
9. Chemical and structural modifications of RNAi therapeutics.
Ku SH; Jo SD; Lee YK; Kim K; Kim SH
Adv Drug Deliv Rev; 2016 Sep; 104():16-28. PubMed ID: 26549145
[TBL] [Abstract][Full Text] [Related]
10. Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics.
Gentile E; Oba T; Lin J; Shao R; Meng F; Cao X; Lin HY; Mourad M; Pataer A; Baladandayuthapani V; Cai D; Roth JA; Ji L
Oncotarget; 2017 Jul; 8(29):48222-48239. PubMed ID: 28637023
[TBL] [Abstract][Full Text] [Related]
11. Folate receptor-targeted nanoparticle delivery of HuR-RNAi suppresses lung cancer cell proliferation and migration.
Muralidharan R; Babu A; Amreddy N; Basalingappa K; Mehta M; Chen A; Zhao YD; Kompella UB; Munshi A; Ramesh R
J Nanobiotechnology; 2016 Jun; 14(1):47. PubMed ID: 27328938
[TBL] [Abstract][Full Text] [Related]
12. Nanoparticles for siRNA-Based Gene Silencing in Tumor Therapy.
Babu A; Muralidharan R; Amreddy N; Mehta M; Munshi A; Ramesh R
IEEE Trans Nanobioscience; 2016 Dec; 15(8):849-863. PubMed ID: 28092499
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic siRNA: principles, challenges, and strategies.
Gavrilov K; Saltzman WM
Yale J Biol Med; 2012 Jun; 85(2):187-200. PubMed ID: 22737048
[TBL] [Abstract][Full Text] [Related]
14. RNAi-based therapeutics and tumor targeted delivery in cancer.
Kara G; Calin GA; Ozpolat B
Adv Drug Deliv Rev; 2022 Mar; 182():114113. PubMed ID: 35063535
[TBL] [Abstract][Full Text] [Related]
15. Low-weight polyethylenimine cross-linked 2-hydroxypopyl-β-cyclodextrin and folic acid as an efficient and nontoxic siRNA carrier for gene silencing and tumor inhibition by VEGF siRNA.
Li JM; Wang YY; Zhang W; Su H; Ji LN; Mao ZW
Int J Nanomedicine; 2013; 8():2101-17. PubMed ID: 23766646
[TBL] [Abstract][Full Text] [Related]
16. Co-delivery of VEGF and Bcl-2 dual-targeted siRNA polymer using a single nanoparticle for synergistic anti-cancer effects in vivo.
Lee SJ; Yook S; Yhee JY; Yoon HY; Kim MG; Ku SH; Kim SH; Park JH; Jeong JH; Kwon IC; Lee S; Lee H; Kim K
J Control Release; 2015 Dec; 220(Pt B):631-41. PubMed ID: 26307351
[TBL] [Abstract][Full Text] [Related]
17. Efficient targeted pDNA/siRNA delivery with folate-low-molecular-weight polyethyleneimine-modified pullulan as non-viral carrier.
Wang J; Dou B; Bao Y
Mater Sci Eng C Mater Biol Appl; 2014 Jan; 34():98-109. PubMed ID: 24268238
[TBL] [Abstract][Full Text] [Related]
18. Theranostic Nanoparticles for RNA-Based Cancer Treatment.
Revia RA; Stephen ZR; Zhang M
Acc Chem Res; 2019 Jun; 52(6):1496-1506. PubMed ID: 31135134
[TBL] [Abstract][Full Text] [Related]
19. Dual antitumoral potency of EG5 siRNA nanoplexes armed with cytotoxic bifunctional glutamyl-methotrexate targeting ligand.
Lee DJ; Kessel E; Edinger D; He D; Klein PM; Voith von Voithenberg L; Lamb DC; Lächelt U; Lehto T; Wagner E
Biomaterials; 2016 Jan; 77():98-110. PubMed ID: 26584350
[TBL] [Abstract][Full Text] [Related]
20. Revisiting the value of competition assays in folate receptor-mediated drug delivery.
Jones SK; Sarkar A; Feldmann DP; Hoffmann P; Merkel OM
Biomaterials; 2017 Sep; 138():35-45. PubMed ID: 28551461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
